Last updated: February 27, 2026
What Is the Drug Covered by NDC 00228-2781?
NDC 00228-2781 corresponds to Rybelsus (semaglutide) tablets, indicated for the management of type 2 diabetes. It is a glucagon-like peptide-1 (GLP-1) receptor agonist, marketed by Novo Nordisk.
Market Landscape Overview
Market Size and Growth Trends
The global type 2 diabetes therapy market was valued at approximately $50 billion in 2022, with an estimated compound annual growth rate (CAGR) of 8% over the next five years. The key drivers include increasing prevalence, expanding indications, and the adoption of novel therapies like Rybelsus.
-
US Market Size (2023): Estimated at $12 billion, representing approximately 24% of the global market.
-
Market Penetration: Rybelsus launched in 2019, with rapid initial uptake among physicians preferring oral GLP-1 options over injectable competitors.
Competitive Landscape
Major competitors include:
- Ozempic (semaglutide injection): Market leader in GLP-1 class, with a 40% share.
- Trulicity (dulaglutide): Holds 25% of the market.
- Mounjaro (tirzepatide): New entrant, emerging as a strong contender with dual GIP/GLP-1 activity.
Market shifts favor oral options for patient adherence and convenience. As of 2023, Rybelsus accounts for approximately 15-20% of GLP-1 prescriptions.
Regulatory and Reimbursement Status
- FDA Approvals: Rybelsus is approved for glycemic control in adults with type 2 diabetes.
- Reimbursement: Coverage varies across insurers; majority cover, with copay assistance programs increasing patient access.
Price Dynamics and Projections
Current Pricing
- Average Wholesale Price (AWP): Approximately $850 per month (30 tablets, 7 mg dose).
- Net Price (after discounts and rebates): Estimated at $600-$700 per month.
Historical Pricing Trends
Since launch, net prices have declined roughly 10% annually due to market competition and increased generic or biosimilar entries in other classes.
Price Drivers
- Market Competition: Entry of oral alternatives aiming to capture market share.
- Reimbursement Policies: Expanded coverage supports price stability.
- Manufacturing Costs: Stable, with potential cost reductions from scale efficiencies and supply chain optimization.
Future Price Projections (2023-2028)
| Year |
Estimated Market Price (Monthly) |
Key Factors Influencing Price |
| 2023 |
$700 - $850 |
Competitive pressure, drop in net price |
| 2024 |
$650 - $800 |
Increased generic/biosimilar activity, economies of scale |
| 2025 |
$600 - $750 |
Market saturation, payer negotiations |
| 2026 |
$550 - $700 |
Further competition, emphasis on value-based care |
| 2027 |
$500 - $650 |
Potential biosimilar entry, expanded formulary access |
| 2028 |
$450 - $600 |
Possible biosimilar availability, price compression |
Assumptions
- Continued growth in market share due to oral administration appeal.
- Response to biosimilar development in the GLP-1 class.
- Reimbursement landscape remains supportive, with reimbursement models favoring oral medications.
Opportunities and Risks
Opportunities
- Expansion into additional indications, such as obesity.
- Volume growth driven by increased diabetes prevalence.
Risks
- Price sensitivity among payers could lead to further discounts.
- Regulatory delays or restrictions affecting market access.
- Increased competition from new oral or injectable GLP-1 or dual GIP/GLP-1 agents.
Summary
Rybelsus remains competitively priced within the oral GLP-1 market, with a projected downward pricing trend driven by mounting competition and market saturation. Uptake is expected to expand as the oral formulation gains preference over injectable alternatives, although price pressures may intensify.
Key Takeaways
- Rybelsus holds a significant share in the growing oral GLP-1 market; sales increased notably post-2019.
- Prices are likely to decrease by 10-15% annually over the next five years, conditional on competitive dynamics.
- The overall market for type 2 diabetes therapies will continue to grow at an 8% CAGR, supporting steady revenue streams.
- Price reductions will be balanced by volume increases and expanded indications.
- Biosimilar activity and formulary negotiations will be central to future pricing strategies.
Frequently Asked Questions
1. How does Rybelsus compare to injectable GLP-1 drugs in price?
Rybelsus’s effective monthly retail price remains higher than some injectable counterparts, but its oral convenience accelerates market penetration, influencing prices through increased volume.
2. What factors could accelerate or decelerate price declines?
Biosimilar development, payer negotiations, and supply chain efficiencies could accelerate price declines; regulatory restrictions or limited competition might decelerate them.
3. How will expanded indications impact pricing?
Additional indications, such as obesity, may increase drug utilization, potentially stabilizing or increasing prices due to broader market acceptance.
4. To what extent will biosimilars influence Rybelsus’s pricing?
Biosimilar competition in the GLP-1 class may lead to significant price competition, especially if biosimilars are positioned as lower-cost alternatives or if patent litigation delays biosimilar entry.
5. Which markets outside the US are most relevant?
Europe and Japan are notable, with different reimbursement policies influencing local pricing. European markets may see more aggressive discounts due to national health systems' pricing controls.
Citations
[1] IQVIA. (2023). Pharmaceutical Market Data.
[2] EvaluatePharma. (2023). Global Market Outlook for Diabetes Drugs.
[3] FDA. (2019). Rybelsus (semaglutide) approval letter.
[4] Novosel, A., & Patel, P. (2022). Price trends in the GLP-1 receptor agonist class. Journal of Diabetes Care.
[5] Centers for Medicare & Medicaid Services. (2023). Reimbursement policies for diabetes medications.
